Mainz Biomed Reports Interim Findings for eAArly DETECT 2 Study

Mainz Biomed N.V., a leader in molecular genetics diagnostics, announced plans to disclose interim results from its eAArly DETECT 2 clinical study by the end of summer 2025. The study focuses on the company's innovative colorectal cancer screening test, integrating proprietary mRNA biomarkers and AI algorithms. With a sample size of around 2,000 patients at average risk, the research aims to validate prior findings and pave the way for transitioning from colorectal cancer (CRC) screening to prevention.

Final study enrollment is projected for late 2025, with top-line results expected in Q4 2025. Depending on these outcomes, Mainz Biomed plans to implement findings in its U.S. pivotal study, ReconAAsense, proposed to start in 2026. The test's goal is not just high-accuracy polyp detection but also preventing CRC through early adenoma identification.